Explore Video

Combination of CDK4/6 inhibitors & aromatase inhibitor is recommended for frontline treatment of Hormone receptor positive (ER+ve) Metastatic Breast Cancer. Patients eventually develop disease progression which might be attributed to ESR1 mutations.

View comprehensive coverage of Breast Cancer from ESMO 2022

There are no randomized clinical trials addressing the continued use of Trastuzumab for Her2 positive MBC patients in prolonged remission and has become important and relevant clinical question.

Bone marrow examination-based diagnosis of MDS with either biopsy or aspirate remains standard of care but is associated with pain, bleeding, difficulty to use the same in elderly patients and hIgh interobserver variability.

Metastatic Triple Negative Breast Cancer is still an unmet medical need.

Several studies carried out by institutions of repute have shown that Dasatinib 50 mg is as effective as 100 mg with less side effects.

Anti-HER2 directed therapy remains the cornerstone of care for individuals with HER2-positive metastatic breast cancer (MBC).

Advanced prostate cancer is characterized by intricate biological changes, including genetic and epigenetic alterations, as well as shifts in cellular metabolism.

Endocrine therapy is the mainstay in the management of patients with Hormone receptor positive (ER+ve) Metastatic Breast Cancer. Tumor progression in ER+ve MBC could be attributed to genomic alterations such as ESR mutations.

TFR strategy is generally safe with adequate monitoring. Restarting TKI after loss of Major Molecular Response is safe with 80% of patients regaining MR4 after restarting TKI treatment.